Literature DB >> 31646567

The carcinogenic complex lncRNA FOXP4-AS1/EZH2/LSD1 accelerates proliferation, migration and invasion of gastric cancer.

R-Y Chen1, Q Ju, L-M Feng, Q Yuan, L Zhang.   

Abstract

OBJECTIVE: To clarify the role of lncRNA FOX4-AS1 in the progression of gastric cancer (GC) via interacting with EZH2/LSD1. PATIENTS AND METHODS: Relative level of FOXP4-AS1 in GC tissues and adjacent normal tissues was determined by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The potential influences of FOXP4-AS1 on cellular behaviors of GC cells were evaluated via a series of functional experiments. Bioinformatics prediction, RNA immunoprecipitation (RIP) assay, and Western blot were conducted to verify the potential of EZH2/LSD1 as a target of FOXP4-AS1.
RESULTS: FOXP4-AS1 was upregulated in GC tissues relative to controls. Its level was higher in GC patients with stage III-IV than those with stage I-II. The survival rate was lower in GC patients presenting the high expression of FOXP4-AS1 compared with those presenting low expression. Transfection of sh-FOXP4-AS1 1# or sh-FOXP4-AS1 2# attenuated proliferative, migratory, and invasive abilities of AGS and BGC7901 cells. FOXP4-AS1 could bind to LSD1 and EZH2, and positively regulated their expression levels. Transfection of sh-LSD1 or sh-EZH2 reduced the proliferative ability of GC cells.
CONCLUSIONS: FOXP4-AS1 binds to EZH2/LSD1 to form a carcinogenic complex, thus accelerating GC cells to proliferate, migrate and invade.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31646567     DOI: 10.26355/eurrev_201910_19148

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.784


  13 in total

1.  Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2.

Authors:  XueHui Liu; XuFeng Zhang; ShuZhang Du
Journal:  Cell Cycle       Date:  2022-01-05       Impact factor: 4.534

2.  SFMBT1 facilitates colon cancer cell metastasis and drug resistance combined with HMG20A.

Authors:  Ruijun Pan; Dingye Yu; Jiajia Hu; Xiao Yang; Chenxing Wang; Luyang Zhang; Pei Xue; Jing Sun; Xiaoping Zhang; Wei Cai
Journal:  Cell Death Discov       Date:  2022-05-16

3.  LncRNA FOXP4-AS1 serves as a biomarker for nasopharyngeal carcinoma diagnosis and prognosis.

Authors:  Lei Yao; TianTian Wang; Xinyan Wang
Journal:  3 Biotech       Date:  2021-01-03       Impact factor: 2.406

4.  LncRNA FOXP4-AS1 Is Involved in Cervical Cancer Progression via Regulating miR-136-5p/CBX4 Axis.

Authors:  Juan Zhao; Ting Yang; Long Li
Journal:  Onco Targets Ther       Date:  2020-03-19       Impact factor: 4.147

5.  LncRNA LINC00511 Acts as an Oncogene in Colorectal Cancer via Sponging miR-29c-3p to Upregulate NFIA.

Authors:  Yu Hu; Ying Zhang; Meng Ding; Ruisi Xu
Journal:  Onco Targets Ther       Date:  2021-01-05       Impact factor: 4.147

Review 6.  The Molecular Roles and Clinical Implications of Non-Coding RNAs in Gastric Cancer.

Authors:  Yanping Yue; Xinrong Lin; Xinyue Qiu; Lei Yang; Rui Wang
Journal:  Front Cell Dev Biol       Date:  2021-12-13

Review 7.  Emerging Roles of LncRNAs in the EZH2-regulated Oncogenic Network.

Authors:  Aixin Hao; Yunxuan Wang; Daniel B Stovall; Yu Wang; Guangchao Sui
Journal:  Int J Biol Sci       Date:  2021-07-25       Impact factor: 6.580

Review 8.  The long and short non-coding RNAs modulating EZH2 signaling in cancer.

Authors:  Sepideh Mirzaei; Mohammad Hossein Gholami; Kiavash Hushmandi; Farid Hashemi; Amirhossein Zabolian; Israel Canadas; Ali Zarrabi; Noushin Nabavi; Amir Reza Aref; Francesco Crea; Yuzhuo Wang; Milad Ashrafizadeh; Alan Prem Kumar
Journal:  J Hematol Oncol       Date:  2022-03-02       Impact factor: 17.388

Review 9.  Interaction of ncRNA and Epigenetic Modifications in Gastric Cancer: Focus on Histone Modification.

Authors:  Qingfan Yang; Yu Chen; Rui Guo; Yalan Dai; Liyao Tang; Yueshui Zhao; Xu Wu; Mingxing Li; Fukuan Du; Jing Shen; Tao Yi; Zhangang Xiao; Qinglian Wen
Journal:  Front Oncol       Date:  2022-01-26       Impact factor: 6.244

10.  FOXP4-AS1 Inhibits Papillary Thyroid Carcinoma Proliferation and Migration Through the AKT Signaling Pathway.

Authors:  Xue Luo; Qingjun Gao; Tian Zhou; Rui Tang; Yu Zhao; Qifang Zhang; Nanpeng Wang; Hui Ye; Xinghong Chen; Song Chen; Wenli Tang; Daiwei Zhao
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.